QCS Session #1 -NABP Implementation of the FDA Compounding MOU

This presentation explains to pharmacists and technicians the Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (MOU), including the responsibilities of the State agency that chooses to sign the MOU in investigating and responding to complaints related to drug products compounding in a state and distributed outside that State and in addressing the interstate distribution of inordinate amounts of compounded human drug products.
In addition, this presentation explains the reporting obligations it places on state boards of pharmacy and, potentially, on licensees in those states. It will explain the relationship between the MOU and the Information Sharing Network (ISN) that NABP developed in partnership with FDA, as well as the types of information they will provide to the ISN. The presentation also will provide an understanding of the potential benefits for licensees who voluntarily enter their compounding information into the ISN, as well as the public health benefits the ISN is envisioned to create.
This presentation leads to better patient care by educating the audience about the background and purpose of the MOU and by informing them about the NABP Information Sharing Network and its role in assisting boards of pharmacy in their efforts to protect public health.